Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTURE-2: M5717 + pyronaridine chemoprevention study in asymptomatic Plasmodium falciparum malaria
PACTR202312609154425Phase 2Recruiting
- Sponsor
- Merck KGaA
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in malaria comparing M5717 + pyronaridine with Atovaquone + proguanil (2 arms). Primary endpoint: Time to parasitemia since negative blood smear after treatment. Started Sep 2023; status: recruiting.
02
Drugs
cabamiquinepyronaridineatovaquoneproguanil
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202312609154425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202312609154425.